NSE: CONCORDBIO · 28 October 2026
- Concord Biotech Ltd. shares declined 7.98% today, settling at ₹1265.60 after opening at ₹1316.90.
- Concord Biotech submitted its standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. Consolidated revenue from operations grew 25.10% year-on-year to ₹309.10 crores, while profit after tax rose 10.30% to ₹69.60 crores. Management noted broad-based growth across product categories and geographies, alongside margin impacts from raw material price movements and product mix.
- Trading volume was 3.72 times the 20-day average daily volume.
Why is Concord Biotech share price falling on 28 October 2026?
Concord Biotech Ltd. shares declined 7.98% today, settling at ₹1265.60 after opening at ₹1316.90.
While the broader Nifty benchmark slipped 0.22%, the sectoral Nifty Pharma index advanced 1.04%, indicating that the sharp downward move in Concord Biotech was specific to the stock rather than reflective of broader sector trends.
The downward price action follows recent corporate updates, including the announcement of financial results for the quarter and half-year ended September 30, 2026, alongside an upcoming bonus share record date set for November 4, 2026. While these developments outline ongoing operational and capital adjustments, the sharp correction appears aligned with profit-taking following strong gains over the prior two sessions.
3.58 lakh shares traded by 28 October 2026 · 03:25 PM IST. This compares with a 20-day average daily volume of 96,185 shares (3.72 times). The five-day average daily volume was 1.23 lakh shares. Separately, the NSE report for 27 October 2026 showed 67,687 shares delivered, representing 43.02% of that day’s traded volume. The same report recorded 22,938 trades.
The stock experienced a sharp correction of 7.98% on high volume despite a positive sector backdrop, following strong positive returns over the preceding two trading sessions.
Latest Company Developments
Concord Biotech submitted its standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. Consolidated revenue from operations grew 25.10% year-on-year to ₹309.10 crores, while profit after tax rose 10.30% to ₹69.60 crores. Management noted broad-based growth across product categories and geographies, alongside margin impacts from raw material price movements and product mix.
Quarterly earnings updates provide direct insight into core operational performance, revenue expansion, and margin trajectories.
The board of directors fixed Wednesday, November 4, 2026, as the record date to determine shareholder eligibility for the previously approved 1:1 bonus equity share issue. Shareholders will receive one new fully paid-up equity share of ₹1 each for every existing fully paid-up equity share held.
Bonus share issuances alter the share capital structure and influence near-term investor engagement.
The company announced the successful completion of a USFDA inspection at its Unit II formulation facility located at Valthera, Ahmedabad. The inspection concluded with one minor procedural observation unrelated to good manufacturing practices (GMP).
Regulatory compliance status directly supports the continuity and expansion of international supply operations.
Concord Biotech Limited has informed the Exchange that Record date for the purpose of Bonus is 04-Nov-2026.
Concord Biotech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 5.84% on 30 September 2026. This compares with 4.40% on 30 June 2026, a change of +1.44 percentage points.
The filing reported 22 MF/UTI holders.
Research & Brokerage Views
Citi reinitiated coverage on Concord Biotech with a Neutral rating amid observations regarding API growth moderation.
Historical Bulk / Block Deals
What to Watch Next
- Share price reaction leading up to and following the November 4, 2026 bonus record date
- Execution of the recently launched dermatology division Inspira
- Progress on commercializing recent USFDA-approved ANDA filings such as Tofacitinib and MMF OS
- Sustained delivery volumes and institutional participation trends
Other Dated Coverage
More Concord Biotech news and dated analysis →
Frequently Asked Questions
What is the latest Concord Biotech company news?
Concord Biotech submitted its standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. Consolidated revenue from operations grew 25.10% year-on-year to ₹309.10 crores, while profit after tax rose 10.30% to ₹69.60 crores. Management noted broad-based growth across product categories and geographies, alongside margin impacts from raw material price movements and product mix.
How strong was Concord Biotech’s trading volume?
3.58 lakh shares traded, 3.72 times the 20-day average daily volume. The price and volume data are dated 28 October 2026 · 03:25 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.